Article
Rheumatology
Ashish J. Mathew, Bente Glintborg, Niels Steen Krogh, Merete L. Hetland, Mikkel Ostergaard
Summary: This study explored the registration, pattern, and burden of clinical enthesitis among routine-care patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in the Danish nationwide DANBIO registry. The results showed that enthesitis was frequent, particularly in women, and associated with a higher disease burden reported by both physicians and patients.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2022)
Article
Medicine, General & Internal
Fan Yang, Chaofan Lu, Huilan Liu, Lei Dou, Yanhong Wang, Hongbin Li, Xinwang Duan, Lijun Wu, Yongfu Wang, Xiuying Zhang, Jian Xu, Jinmei Su, Dong Xu, Jiuliang Zhao, Qingjun Wu, Mengtao Li, Xiaomei Leng, Xiaofeng Zeng
Summary: Enthesitis is common in Chinese patients with PsA, and it is important to evaluate both peripheral and axial sites. Compared with other cohorts, Chinese patients with enthesitis tend to be younger, have a lower body mass index, a higher rate of positive HLA-B27, more frequent dactylitis, and a higher proportion of csDMARDs use.
CHINESE MEDICAL JOURNAL
(2023)
Article
Rheumatology
Alexander Egeberg, Nana Aviaaja Lippert Roseno, David Aagaard, Erik Hillo Lorup, Mia-Louise Nielsen, Lea Nymand, Lars Erik Kristensen, Jacob P. Thyssen, Simon Francis Thomsen, Rene Lindholm Cordtz, Nikolai Loft, Lone Skov, Lars Erik Bryld, Mads Kirchheiner Rasmussen, Pil Hojgaard, Salome Kristensen, Lene Dreyer
Summary: This study examined the real-life drug survival of biologics and novel small-molecule therapies for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis. Results showed varying treatment responses to drugs with different mechanisms of action across the diseases, emphasizing the need for individualized treatment approaches.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2022)
Article
Rheumatology
Bente Glintborg, Dorte Vendelbo Jensen, Sara Engel, Lene Terslev, Mogens Pfeiffer Jensen, Oliver Hendricks, Mikkel Ostergaard, Simon Horskjaer Rasmussen, Thomas Adelsten, Ada Colic, Kamilla Danebod, Malene Kildemand, Anne Gitte Loft, Heidi Lausten Munk, Jens Kristian Pedersen, Rene Drage Ostgard, Christian Moller Sorensen, Niels Steen Krogh, Jette Agerbo, Connie Ziegler, Merete Hetland
Summary: This study investigated self-protection strategies, health behavior, and medication adherence in Danish patients with inflammatory rheumatic diseases during the initial phase of the COVID-19 pandemic and after the society reopening. Results showed widespread anxiety and self-isolation among patients, but high medication adherence. Factors associated with anxiety and self-isolation included female gender, comorbidities, unemployment, lower education, biological treatment, and poor quality of life.
Article
Public, Environmental & Occupational Health
P. A. Jacobsen, M. P. Andersen, G. Gislason, M. Phelps, J. H. Butt, L. Kober, M. Schou, E. Fosbol, H. C. Christensen, C. Torp-Pedersen, T. Gerds, U. M. Weinreich, K. Kragholm
Summary: This study aimed to investigate the return to work after COVID-19 and how the severity of the disease affects it. The study found that hospitalized patients have a lower chance of returning to work, and factors such as female sex, older age, and comorbidity are associated with a lower chance of returning to work.
Article
Dermatology
Claudio Lembo, Annunziata Raimondo, Amato de Paulis, Ilaria Mormile, Francesca Wanda Rossi, Serena Lembo, Anna Balato
Summary: Psoriasis and psoriatic arthritis are inflammatory diseases that are related, with psoriatic patients' skin locations being linked to osteoclast generation.
EXPERIMENTAL DERMATOLOGY
(2021)
Article
Rheumatology
Laura Pina Vegas, Lea Hoisnard, Lea Bastard, Emilie Sbidian, Pascal Claudepierre
Summary: This study compares the long-term persistence of different classes of biologics in PsA patients who have previously been treated with TNFi. The results show that the use of IL-17i or IL-12/23i is associated with higher persistence compared to TNFi.
Article
Cardiac & Cardiovascular Systems
Saranda Haxha, Andrim Halili, Morten Malmborg, Ulrik Pedersen-Bjergaard, Berit T. Philbert, Tommi B. Lindhardt, Soeren Hoejberg, Anne-Marie Schjerning, Martin H. Ruwald, Gunnar H. Gislason, Christian Torp-Pedersen, Casper N. Bang
Summary: The present study aimed to determine the association between Type 2 diabetes mellitus (T2DM) and third-degree (complete) atrioventricular block. The results showed that T2DM was significantly associated with third-degree atrioventricular block, and this association remained in subgroups with other comorbidities.
EUROPEAN HEART JOURNAL
(2023)
Article
Rheumatology
Paolo Gisondi, Francesco Bellinato, Giovanni Targher, Luca Idolazzi, Giampiero Girolomoni
Summary: In patients with moderate-to-severe chronic plaque psoriasis, treatment with bDMARDs may delay or reduce the risk of incident PsA. The annual incidence rate of PsA was significantly lower in the bDMARDs group compared to the phototherapy group. Factors associated with a higher risk of PsA included older age, nail psoriasis, and psoriasis duration over 10 years.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Alexis Ogdie, Mei Liu, Meghan Glynn, Kelechi Emeanuru, Leslie R. Harrold, Sven Richter, Benoit Guerette, Philip J. Mease
Summary: The study found that apremilast monotherapy is an effective option for patients with oligoarticular PsA. Apremilast initiators experienced greater disease activity improvements at follow-up compared to MTX initiators.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Sofia Exarchou, Daniela Di Giuseppe, Eva Klingberg, Valgerdur Sigurdardottir, Sara Wedren, Ulf Lindstroem, Carl Turesson, Lennart T. H. Jacobsson, Johan Askling, Johan K. Wallman
Summary: This study compared the all-cause mortality and causes of death between patients with psoriatic arthritis (PsA) and the general population in Sweden. The findings showed that PsA patients had a slightly higher all-cause mortality rate compared to the general population, mainly driven by increased risks in women and patients with longer disease duration. However, after adjusting for comorbidity, the elevated mortality risk in PsA disappeared. The leading causes of death were cardiovascular disease and malignancy.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Dermatology
Anke Koenig, Matthias Hofmann, Roland Kaufmann, Jutta Mueller-Stahl, Andreas Pinter
Summary: PsA patients are primarily diagnosed by rheumatologists at an early or intermediate stage and treated by dermatologists, especially with the use of biologics in university hospitals. Effective collaboration between rheumatologists and dermatologists is crucial for optimal treatment outcomes.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Article
Rheumatology
Alexis Ogdie, Peter Hur, Mei Liu, Sabrina Rebello, Robert R. McLean, Blessing Dube, Meghan Glynn, Philip J. Mease
Summary: In this US-based study, the majority of patients with psoriatic arthritis demonstrated multidomain disease presentations, which correlated with worse disease activity, quality of life, and work productivity measures. This emphasizes the heterogeneity of psoriatic arthritis and the significance of assessing all disease domains for optimal disease management.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Serife Gul Karadag, Taner Coskuner, Fatma Gul Demirkan, Hafize Emine Sonmez, Semanur Ozdel, Mustafa Cakan, Gulcin Otar Yener, Kubra Ozturk, Ferhat Demir, Betul Sozeri, Nuray Aktay Ayaz
Summary: This study describes the clinical features and treatment outcomes of children with juvenile psoriatic arthritis (JPsA) and compares the different patterns of the disease between early-onset and late-onset age groups. The study found that about one-third of JPsA patients do not have psoriasis at the time of diagnosis, and children with PsA seem to display two different phenotypes.
Article
Biochemistry & Molecular Biology
Andrea Becciolini, Simone Parisi, Patrizia Del Medico, Antonella Farina, Elisa Visalli, Aldo Biagio Molica Colella, Federica Lumetti, Rosalba Caccavale, Palma Scolieri, Romina Andracco, Francesco Girelli, Elena Bravi, Matteo Colina, Alessandro Volpe, Aurora Ianniello, Maria Chiara Ditto, Valeria Nucera, Veronica Franchina, Ilaria Plate, Eleonora Di Donato, Giorgio Amato, Carlo Salvarani, Simone Bernardi, Gianluca Lucchini, Francesco De Lucia, Francesco Molica Colella, Daniele Santilli, Natalia Mansueto, Giulio Ferrero, Antonio Marchetta, Eugenio Arrigoni, Rosario Foti, Gilda Sandri, Vincenzo Bruzzese, Marino Paroli, Enrico Fusaro, Alarico Ariani
Summary: This retrospective observational study aimed to report the long-term disease activity index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and analyze the predictors of clinical response. The study found that almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. Baseline DAPSA was the only factor associated with achieving low disease activity or remission at both 6 and 12 months.
Article
Rheumatology
M. A. Nielsen, D. Koster, S. Greisen, A. Troldborg, K. Stengaard-Pedersen, P. Junker, K. Horslev-Petersen, M. L. Hetland, M. Ostergaard, M. Hvid, H. Leffler, T. W. Kragstrup, B. Deleuran
Summary: The study found that patients with rheumatoid arthritis (RA) had persistently increased levels of galectin-3 (Gal-3) in their plasma, and changes in Gal-3 levels were associated with long-term disease activity. Gal-3 levels in synovial fluid were also significantly elevated. In vitro experiments showed that a Gal-3 inhibitor could reduce the activity of inflammatory cells.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B. McInnes, Naveed Sattar, Tanja A. Stamm, Tsutomu Takeuchi, Michael Trauner, Desiree van der Heijde, Marieke Voshaar, Kevin L. Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Ruediger R. Burmester, Johannes W. J. Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H. Choy, Catalin Codreanu, Bernard Combe, Mary K. Crow, Maarten de Wit, Paul Emery, Roy M. Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L. Hyrich, Annamaria Iagnocco, John D. Isaacs, Joel M. Kremer, Xavier Mariette, Peter Merkel, Eduardo F. Mysler, Peter Nash, Michael T. Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S. Smolen
Summary: This paper is an updated consensus document on the medical use of IL-6 pathway inhibition in the treatment of inflammatory diseases. The document provides comprehensive consensus statements based on systematic literature research and expert opinion, covering various aspects of IL-6 pathway inhibitors, including dosing, indications, and clinical considerations.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Bente Glintborg, Daniela Di Giuseppe, Johan K. Wallman, Sella A. Provan, Dan Nordstrom, Anna-Mari Hokkanen, Jenny Osterlund, Eirik Kristianslund, Tore K. Kvien, Bjorn Gudbjornsson, Merete Lund Hetland, Brigitte Michelsen, Lennart Jacobsson, Johan Askling, Ulf Lindstrom
Summary: This study aims to assess the safety of secukinumab and TNF inhibitors in the treatment of SpA and PsA. The study found that the risk of hospitalized infection during the first year of treatment with secukinumab was higher compared to adalimumab, potentially due to confounding factors.
Article
Rheumatology
Kristine M. Latocha, Katrine B. Loppenthin, Mikkel Ostergaard, Poul J. Jennum, Merete L. Hetland, Henrik Rogind, Tine Lundbak, Julie Midtgaard, Robin Christensen, Bente A. Esbensen
Summary: The objective of the study was to compare the effects of cognitive behavioural therapy for insomnia (CBT-I) to usual care on sleep efficiency. The study found that CBT-I did not significantly improve sleep efficiency measured by polysomnography (PSG). However, CBT-I showed significant improvement in patient-reported sleep and RA-related outcomes.
Article
Rheumatology
M. B. Raft, M. L. Hetland, C. H. Brahe, K. Horslev-Petersen, L. Midtboll Ornbjerg, P. Junker, N. Biln, K. Stengaard-Pedersen, M. Ostergaard
Summary: This study evaluated the predictive role of serum 14-3-3 eta for disease activity and radiographic progression in early RA patients. The results showed that 14-3-3 eta can predict the risk of radiographic progression, especially in ACPA-negative patients.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
E. B. Rasmussen, L. S. Thiele, K. Stengaard-Pedersen, M. L. Hetland, K. Horslev-Petersen, P. Junker, M. Ostergaard, A. S. Hansen, M. Hvid, B. Deleuran, S. R. Greisen
Summary: ACPAs IgA and IgG have weak associations with disease activity in early RA, but are not superior in predicting long-term radiographic progression.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Cell Biology
Morten A. A. Nielsen, Ditte Koster, Akul Y. Y. Mehta, Kristian Stengaard-Pedersen, Pierre Busson, Peter Junker, Kim Horslev-Petersen, Merete Lund Hetland, Mikkel ostergaard, Malene Hvid, Hakon Leffler, Tue W. W. Kragstrup, Richard D. D. Cummings, Bent Deleuran
Summary: This study evaluated the clinical and pathogenic aspects of Gal-9 in rheumatoid arthritis (RA) and found that it plays a role in modulating synovial FLS activities and maintaining subclinical disease activity.
Article
Rheumatology
Bente Glintborg, Daniela Di Giuseppe, Johan Karlsson Wallman, Dan C. Nordstrom, Bjorn Gudbjornsson, Merete Lund Hetland, Johan Askling, Gerdur Grondal, Tuulikki Sokka, Sella A. Provan, Brigitte Michelsen, Eirik Klami Kristianslund, Lene Dreyer, Thorvardur Jon Love, Ulf Lindstrom
Summary: This study aimed to describe the uptake and effectiveness of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) in the Nordic countries. The results showed that the uptake of newer b/tsDMARDs increased from 2014 and plateaued in 2018. Regardless of treatment course, only a minority of patients starting a second or later b/tsDMARD course remained on drug and achieved low disease activity (LDA).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Health Care Sciences & Services
L. H. Lindgren, T. Thomsen, A. de Thurah, M. Aadahl, M. L. Hetland, S. D. Kristensen, B. A. Esbensen
Summary: The aim of this study was to develop a self-management intervention for newly diagnosed patients with IA. Through literature reviews and workshops, a nurse-led 9-month intervention was developed, incorporating the participation of a physiotherapist and an occupational therapist, with a focus on medical, role, and emotional management.
BMC HEALTH SERVICES RESEARCH
(2023)
Article
Rheumatology
Louise Linde, Lykke M. Ornbjerg, Stylianos Georgiadis, Simon H. Rasmussen, Ulf Lindstrom, Johan Askling, Brigitte Michelsen, Daniela Di Giuseppe, Johan K. Wallman, Bjorn Gudbjornsson, Thorvardur Jon Love, Dan C. Nordstrom, Timo Yli-Kerttula, Lucie Nekvindova, Jiri Vencovsky, Florenzo Iannone, Alberto Cauli, Anne Gitte Loft, Bente Glintborg, Karin Laas, Ziga Rotar, Matija Tomsic, Gary J. Macfarlane, Burkhard Moller, Marleen van de Sande, Catalin Codreanu, Michael J. Nissen, Merih Birlik, Sukran Erten, Maria J. Santos, Elsa Vieira-Sousa, Merete L. Hetland, Mikkel Ostergaard
Summary: In bio-naive patients with PsA initiating a TNF inhibitor (TNFi), baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission and moderate response at 6 months, as well as drug retention at 12 months were identified, indicating potential generalizability from country to disease level.
Article
Rheumatology
Rasmus Westermann, Rene Lindholm Cordtz, Kirsten Duch, Lene Mellemkjaer, Merete Lund Hetland, Andrea Michelle Burden, Lene Dreyer
Summary: This study examined the risk of first primary cancer in patients with rheumatoid arthritis (RA) treated with janus kinase inhibitors (JAKi) compared to those treated with biologic disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting. The results showed that JAKi treatment was not associated with a statistically significant increased risk of first primary cancer compared to bDMARDs treatment in RA patients.
Article
Rheumatology
Mikkel Ostergaard, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordstrom, Michael T. Nurmohamed, Bjorn Gudbjornsson, Lykke Midtboll Ornbjerg, Pernille Boyesen, Kristina Lend, Kim Horslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur Grondal, Simon Krabbe, Joakim Lindqvist, Inger Gjertsson, Daniel Glinatsi, Meliha Crnkic Kapetanovic, Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljosa, Eli Brodin, Hanne Lindegaard, Annika Soderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Soren Andreas Just, David J. Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A. Haavardsholm, Jon Lampa, NORD-STAR Study Grp
Summary: This study compared the clinical and radiographic outcomes of different biological treatments with active conventional therapy in patients with early rheumatoid arthritis (RA). The results showed that abatacept and certolizumab pegol had higher clinical remission rates compared to active conventional therapy, while tocilizumab did not show significant differences. Radiographic progression was low and similar across treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Louise Linde, Lykke Midtboll Ornbjerg, Cecilie Heegaard Brahe, Johan Karlsson Wallman, Daniela Di Giuseppe, Jakub Zavada, Isabel Castrejon, Federico Diaz-Gonzalez, Ziga Rotar, Matija Tomsic, Bente Glintborg, Bjorn Gudbjornsson, Arni Jon Geirsson, Brigitte Michelsen, Eirik Klami Kristianslund, Maria Jose Santos, Anabela Barcelos, Dan Nordstrom, Kari K. Eklund, Adrian Ciurea, Michael Nissen, Servet Akar, Lise Hejl Hyldstrup, Niels Steen Krogh, Merete Lund Hetland, Mikkel Ostergaard
Summary: This study investigated the real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and its association with treatment line and reasons for withdrawal. The results showed similar drug retention rates for the second and third TNFi, but lower remission rates for the third TNFi. Additionally, higher remission rates were observed for the second TNFi if the withdrawal reason from the preceding TNFi was adverse events (AE).